T. Rowe Price Associates
INDV icon

T. Rowe Price Associates’s Indivior Pharmaceuticals INDV Stock Holding History

T. Rowe Price Associates’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.24M Buy
138,950
+24,043
+21% +$794K ﹤0.01% 1488
2025
Q4 		$4.12M Buy
114,907
+28,746
+33% +$878K ﹤0.01% 1461
2025
Q3 		$2.08M Buy
86,161
+25,596
+42% +$536K ﹤0.01% 1715
2025
Q2 		$893K Buy
+60,565
New +$705K ﹤0.01% 2036

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates's INDV Position: Q1 2026 in Review

T. Rowe Price Associates increased its Indivior Pharmaceuticals (INDV) stake by 21% in Q1 2026, buying an estimated $794K and bringing the position to 138,950 shares worth $4.24M. The position accounts for ﹤0.01% of the portfolio, ranked #1488.

T. Rowe Price Associates first reported a position in INDV in Q2 2025 and has held it in 4 quarters since. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • T. Rowe Price Associates held 138,950 shares of Indivior Pharmaceuticals worth $4.24M as of Q1 2026.
  • T. Rowe Price Associates bought 24,043 Indivior Pharmaceuticals shares in Q1 2026, an estimated $794K.
  • Indivior Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1488 holding.
  • T. Rowe Price Associates first reported a position in Indivior Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.